Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:age |
12 years and older
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
gptkb:Lancet
gptkb:India Phase 3 approximately 28,000 |
| gptkbp:delivers |
needle-free injector
|
| gptkbp:developed_by |
gptkb:Zydus_Cadila
|
| gptkbp:distribution |
gptkb:healthcare_organization
|
| gptkbp:dosage_form |
gptkb:3
not required for primary series |
| gptkbp:effective_date |
August 2021
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zy Co V-D
|
| gptkbp:innovation |
first DNA vaccine approved for human use
|
| gptkbp:is_documented_in |
gptkb:battle
|
| gptkbp:is_effective_against |
66.6% in preventing symptomatic COVID-19
|
| gptkbp:is_vulnerable_to |
gptkb:government_agency
affordable ongoing studies recombinant DNA government and private sector strong immune response preventive vaccine campaigns conducted collaborations with health organizations effective against variants adverse event reporting system high effectiveness against severe disease reduces hospitalization rates 3 doses required multicenter trials conducted. |
| gptkbp:manager |
intradermal
|
| gptkbp:manufacturer |
gptkb:Zydus_Cadila_Healthcare_Ltd.
|
| gptkbp:market |
gptkb:stock_market_index
ongoing |
| gptkbp:operating_hours |
0, 28, and 56 days
|
| gptkbp:origin |
gptkb:India
|
| gptkbp:regulatory_compliance |
gptkb:Indian_government
DCGI approval |
| gptkbp:safety_features |
well-tolerated
|
| gptkbp:side_effect |
mild to moderate reactions
|
| gptkbp:supply_chain |
cold chain required
|
| gptkbp:target_audience |
adolescents and adults
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:technology |
plasmid DNA technology
|
| gptkbp:type |
DNA vaccine
|